Dr Erica Stringer-Reasor of UAB discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next for HR+/HER2- breast cancer care.
Erica Stringer-Reasor, MD
Advertisement
Erica Stringer-Reasor, MD, is an associate professor of medicine and director of the Breast Cancer Program at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
Articles by Erica Stringer-Reasor, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Community Clinical Trials and the Lung Cancer Pipeline
2
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
3
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
4
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
5